Lynch syndrome
MONDO:0005835An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.
Also known as: Hereditary colorectal endometrial cancer syndrome, Hereditary non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2), Hereditary nonpolyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2), Lynch syndrome, familial non-polyposis colon cancer (hMSH2, hMLH1, hPMS1, hPMS2), hereditary defective mismatch repair syndrome
2976 clinical trials for this condition and its sub-types, 81 tagged with Lynch syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lynch syndrome
-
Lynch syndrome 1 5 trials
-
Lynch syndrome 2 3 trials
-
Lynch syndrome 4 0 trials
-
Lynch syndrome 5 0 trials
-
Lynch syndrome 8 0 trials
-
New vaccine aims to train immune system against lynch syndrome cancers
Vaccine OngoingThis study tests a vaccine called Nous-209 in 45 people with Lynch syndrome, a genetic condition that raises the risk of colon and other cancers. The vaccine is made from man-made copies of proteins that cancer cells produce, aiming to teach the immune system to recognize and att…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Vaccine
Last updated Jun 27, 2026 09:10 UTC
-
Immunotherapy before surgery shows promise for certain colorectal cancers
Disease control OngoingThis trial is testing whether giving the immunotherapy drug pembrolizumab before surgery can improve outcomes for people with high-risk stage 2 or stage 3 colorectal cancer that has a specific genetic feature called mismatch repair deficiency. About 88 participants will receive p…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a walking routine alter cancer biomarkers? new trial investigates
Disease control OngoingThis study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Immunotherapy combo aims to prevent colon cancer return in High-Risk patients
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help prevent cancer from coming back in people with stage III colon cancer that has a specific DNA repair defect (dMMR). About 712 participants will receive either chemo …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could an immune booster help kids fight deadly brain cancer?
Disease control OngoingThis early-stage trial is testing the safety and potential benefit of pembrolizumab, an immunotherapy drug, in 71 children whose brain tumors (like DIPG, high-grade gliomas, or medulloblastoma) have come back or not responded to standard treatments. The drug works by helping the …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Digital assistant aims to close gaps in hereditary cancer care
Disease control By invitation onlyThis trial tests a digital tool that helps doctors and patients manage cancer risks linked to hereditary syndromes like BRCA-related breast/ovarian cancer and Lynch syndrome. The tool provides personalized recommendations during primary care visits. Researchers compare care gaps,…
Sponsor: HealthPartners Institute • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy cocktail targets Hard-to-Treat bowel cancer
Disease control OngoingThis Phase 2 trial tests a combination of pembrolizumab (Keytruda) and quavonlimab against other drug combos in 302 people with stage IV colorectal cancer that has a specific genetic feature (MSI-H or dMMR). The goal is to see if the new combo shrinks tumors better and for longer…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to outsmart resistant colorectal cancer
Disease control OngoingThis trial tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has not responded to standard immunotherapy. The drug is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) to potentially reactivate the immune system agains…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Childhood cancer immunotherapy trial pulled before it started
Disease control CancelledThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drug combination was safe and could shrink tumors. …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Immunotherapy cocktail targets tough cancers
Disease control OngoingThis study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with radiation therapy can control or shrink tumors in people with colorectal or pancreatic cancer that has specific genetic features (MSS or MSI-high). About 84 adults with advanced disease are…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug XmAb20717 tested in rare cancers – trial suspended
Disease control PausedThis phase II trial tests the safety and effectiveness of a drug called XmAb20717 in 140 people with advanced rare cancers, including mesothelioma, lymphoma, and small cell lung cancer. The drug is given by IV. The main goal is to see if tumors shrink. The trial is currently susp…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Weight loss program aims to cut cancer risk in BRCA and lynch syndrome carriers
Disease control OngoingThis study tests a weight management and health behavior program for people with BRCA or Lynch syndrome mutations, who have a higher risk of certain cancers. Participants receive diet tracking, exercise guidance, phone coaching, and online support to help them lose weight and ado…
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New program aims to close cancer screening gaps for rural families
Disease control By invitation onlyThis study tests a two-year follow-up program for 200 adults with hereditary cancer syndromes like BRCA or Lynch syndrome. Participants get personalized care plans and regular check-ins with a genetics doctor to help them follow cancer prevention and screening guidelines. The goa…
Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug duo shows promise for tough colorectal cancer
Disease control OngoingThis phase II trial is testing whether combining two drugs—niraparib and panitumumab—can help people with advanced colorectal cancer that has spread. The study includes 26 patients whose cancer has not responded to at least one prior treatment. The goal is to see if the combinati…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Could a vaccine stop colon cancer in lynch syndrome patients?
Prevention OngoingThis phase IIb trial tests whether a vaccine called Tri-Ad5, combined with an immune booster N-803, can prevent colon cancer in people with Lynch syndrome. The vaccine targets proteins found in precancer and cancer cells, aiming to train the immune system to destroy them. 186 par…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New program aims to boost genetic testing in cancer families
Knowledge-focused OngoingThis study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study hopes to outsmart pancreatic cancer by gathering clues
Knowledge-focused OngoingThis study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Gut bacteria may hold key to cancer risk in lynch syndrome
Knowledge-focused OngoingThis study looks at how bacteria living in the gut and diet might influence colorectal cancer risk in people with Lynch syndrome and other inherited colon conditions. Researchers will collect stool samples, colon biopsies, and diet questionnaires from 77 participants during routi…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Lynch syndrome Patients' screening habits under the microscope
Knowledge-focused OngoingThis study looks at whether people with Lynch Syndrome—a condition that raises the risk for several cancers—follow recommended screening guidelines after genetic counseling. Researchers will track about 1,530 participants to see who gets the suggested tests and what factors help …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC